Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
  2. Our Websites |
  3. Global Business Websites |
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce Increase  

Internal Medicine

Contact Us

sanofi-aventis (Malaysia) Sdn. Bhd. (334110-P)

Unit TB-18-1, Level 18
Tower B, Plaza 33
No.1 Jalan Kemajuan, Seksyen 13
46200 Petaling Jaya

Tel : +603 7651 0800
Fax: +603 7651 0801/2

Content :

Internal Medicine

Internal medicine is the practice of preventing and treating general diseases. sanofi-aventis’ internal medicine portfolio includes for a wide range of general medical conditions such as, benign prostatic hyperplasia, osteoporosis and rheumatoid arthritis.



Osteoporosis is a progressive disease characterized by low bone mineral density (BMD) and bone deterioration – conditions that reduce skeletal strength and increase the risk of bone fracture. It occurs when bone is resorbed (dissolved) by the body faster than new bone is produced. Osteoporosis is primarily a disease of the elderly, and postmenopausal hormonal changes are a principal contributing factor. Although hormonal changes are the underlying cause of osteoporosis, other factors such as body type (small build), race (Caucasian or Asian), poor dietary calcium intake, smoke habit, and age raise susceptibility to osteoporosis. Osteoporosis can also be caused by steroid-induced hormonal changes and is a well-documented side effect of sustained systemic steroid use. 

Rheumatoid arthritis

Rheumatoid arthritis is a debilitating autoimmune disease with the joint lining tissue (synovium) as the primary target. An immune reaction allows mediators to enter cells, leading to inflammation and destruction involving cartilage and bone and resulting in damage to joints and ligaments. It affects between 0.5 and 1% of the population. Onset is generally between 35 and 55 years. It is three to four times more frequent in women. Anti-rheumatic drugs are classified as symptom-modifying, disease-modifying or disease-controlling (no drugs are currently available for this category).

Benign prostatic hyperplasia

Benign prostatic hyperplasia is a common condition in men over 50 is caused by uncontrolled growth of non-cancerous cells in the prostate gland. Research shows that 50% of the men in their 60s and as many as 80% in their 80s need treatment.

Updated August 28, 2009

Module :